Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (FWO/G093218N)
Fonds Wetenschappelijk Onderzoek (1292326N)
Onderzoeksraad, KU Leuven (C24-17-063)
- License Information
-
More Information
Article History
Received: 20 November 2025
Accepted: 20 December 2025
First Online: 16 January 2026
Declarations
:
: The study was approved by the local Ethics Committee UZ/KU Leuven and was conducted according to the latest version of the Declaration of Helsinki. The participant signed a written informed consent prior to study participation and agreed that the obtained data could be used for other scientific purposes and publications. This study is part of a larger, multimodal, multitracer imaging study (Registered on ClinicalTrials.gov: NCT03514524 at 2018-05-02, retrospectively registered).
: K.V.L. has performed contract research through KU Leuven for Merck, Johnson&Johnson, UCB, Syndesi, Eikonizo, GE Healthcare, Cerevel, BMS and Curasen and is an advisory board member of Enigma. The other authors have no relevant financial or non-financial interests to disclose.
